Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats
Autore:
Ballard, TM; McAllister, KH;
Indirizzi:
Novartis Pharma Inc, Nervous Syst Dept, CH-4002 Basel, Switzerland Novartis Pharma Inc Basel Switzerland CH-4002 CH-4002 Basel, Switzerland
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 1, volume: 146, anno: 1999,
pagine: 10 - 18
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALZHEIMERS-DISEASE; POSITION TASK; CHOLINERGIC DEFICITS; SENILE DEMENTIA; SPATIAL MEMORY; TO-SAMPLE; PERFORMANCE; LESIONS; FORNIX; DRUGS;
Keywords:
delayed non-matching to position task scopolamine; ENA 713; Exelon; working memory; rat;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: McAllister, KH Novartis Pharma Inc, Nervous Syst Dept, WSJ-386-226, CH-4002 Basel, Switzerland Novartis Pharma Inc WSJ-386-226 Basel Switzerland CH-4002
Citazione:
T.M. Ballard e K.H. McAllister, "The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats", PSYCHOPHAR, 146(1), 1999, pp. 10-18

Abstract

Rationale: The disruption of working memory in the delayed non-matching toposition (DNMTP) task by the muscarinic antagonist, scopolamine, is considered to be a model of the spatial working memory deficit in Alzheimer's disease (AD) patients. Objective: To investigate whether ENA 713 (Exelon) (0.1, 0.5 mg/kg, IP), an acetylcholinesterase inhibitor. would reverse the effects of scopolamine in the DNMTP task, Methods: Male Lister Hooded rats weretrained to criterion in an operant DNMTP task (0- to 16-s delay intervals)before receiving vehicle, scopolamine (0.05 mg/kg, SC) alone, ENA 713 (0.1, 0.5 mg/kg, IP) alone, or combinations of scopolamine and ENA 713, in two variations of the task - with and without barriers inserted between the food magazine and the two levers. Barriers were inserted to prevent the use ofpositional strategies to perform the task, since this behaviour may confound the conclusions of the effect of drugs on working memory. Results: It was found that: (i) scopolamine significantly reduced choice accuracy delay-dependently in both test situations while modifying non-mnemonic measures oftask performance delay-independently, indicating an impairment of working memory, (ii) ENA 713 (0.5 mg/kg) significantly attenuated the scopolamine-induced impairment of working memory and significantly reduced the scopolamine-induced changes in some non-mnemonic measures of task performance; (iii)the presence of barriers did not alter the effects of scopolamine and ENA 713 on working memory. Conclusion: ENA 713 reversed the working memory deficit induced by scopolamine. These results are consistent with the attenuation of learning and memory disruptions due to cholinergic dysfunction by ENA713 in other preclinical assays, and predict a drug-induced improvement inworking memory in AD patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 11:49:07